Literature DB >> 17911155

Polyglutamine diseases: emerging concepts in pathogenesis and therapy.

Jieya Shao1, Marc I Diamond.   

Abstract

Polyglutamine diseases are a family of neurodegenerative conditions that each derive from a CAG triplet repeat expansion in a specific gene. This produces a pathogenic protein that contains a critically expanded tract of glutamines. These prototypical protein misfolding disorders include Huntington disease, spinobulbar muscular atrophy, dentatorubral-pallidoluysian atrophy and several spinocerebellar ataxias. This article reviews the emerging concepts in pathogenesis and therapy. Key ideas include the role of proteolytic cleavage, the importance of conformational change in the pathogenic proteins, the role of protein aggregation and the importance of transcriptional and metabolic disturbances. The relative role of functional perturbation in a target protein induced by a polyglutamine expansion is also discussed. Therapeutic strategies include counteracting cellular perturbations and direct targeting of polyglutamine protein expression, cleavage or conformation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17911155     DOI: 10.1093/hmg/ddm213

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  104 in total

Review 1.  Recent advances in the genetics of cerebellar ataxias.

Authors:  Anna Sailer; Henry Houlden
Journal:  Curr Neurol Neurosci Rep       Date:  2012-06       Impact factor: 5.081

2.  Expanded polyglutamine-binding peptoid as a novel therapeutic agent for treatment of Huntington's disease.

Authors:  Xuesong Chen; Jun Wu; Yuan Luo; Xia Liang; Charlene Supnet; Mee Whi Kim; Gregor P Lotz; Guocheng Yang; Paul J Muchowski; Thomas Kodadek; Ilya Bezprozvanny
Journal:  Chem Biol       Date:  2011-09-23

3.  Nicotinamide improves motor deficits and upregulates PGC-1α and BDNF gene expression in a mouse model of Huntington's disease.

Authors:  Tyisha Hathorn; Abigail Snyder-Keller; Anne Messer
Journal:  Neurobiol Dis       Date:  2010-08-22       Impact factor: 5.996

4.  Discovery and characterization of a mammalian amyloid disaggregation activity.

Authors:  Amber N Murray; James P Solomon; Ya-Juan Wang; William E Balch; Jeffery W Kelly
Journal:  Protein Sci       Date:  2010-04       Impact factor: 6.725

5.  In vivo cell-autonomous transcriptional abnormalities revealed in mice expressing mutant huntingtin in striatal but not cortical neurons.

Authors:  Elizabeth A Thomas; Giovanni Coppola; Bin Tang; Alexandre Kuhn; SoongHo Kim; Daniel H Geschwind; Timothy B Brown; Ruth Luthi-Carter; Michelle E Ehrlich
Journal:  Hum Mol Genet       Date:  2010-12-20       Impact factor: 6.150

Review 6.  Current understanding on the pathogenesis of polyglutamine diseases.

Authors:  Xiao-Hui He; Fang Lin; Zheng-Hong Qin
Journal:  Neurosci Bull       Date:  2010-06       Impact factor: 5.203

7.  Moving toward a gene therapy for Huntington's disease.

Authors:  J C Glorioso; J B Cohen; D L Carlisle; I Munoz-Sanjuan; R M Friedlander
Journal:  Gene Ther       Date:  2015-12       Impact factor: 5.250

Review 8.  Animal models of polyglutamine diseases and therapeutic approaches.

Authors:  J Lawrence Marsh; Tamas Lukacsovich; Leslie Michels Thompson
Journal:  J Biol Chem       Date:  2008-10-28       Impact factor: 5.157

Review 9.  Mitochondrial calcium function and dysfunction in the central nervous system.

Authors:  David G Nicholls
Journal:  Biochim Biophys Acta       Date:  2009-03-17

10.  Nucleocytoplasmic shuttling of p62/SQSTM1 and its role in recruitment of nuclear polyubiquitinated proteins to promyelocytic leukemia bodies.

Authors:  Serhiy Pankiv; Trond Lamark; Jack-Ansgar Bruun; Aud Øvervatn; Geir Bjørkøy; Terje Johansen
Journal:  J Biol Chem       Date:  2009-12-15       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.